On September 15, 2022, Pfizer announced the top line results from its Phase 3 clinical trial showing that its investigational pentavalent meningococcal vaccine (MenABCWY) demonstrated non-inferiority to licensed vaccines for the five meningococcal serogroups that cause the majority of invasive meningococcal disease: serogroups A, B, C, W and Y.)

Today, there are approximately 52 million adolescents and young adults who are in the age range recommended for meningococcal vaccination according to Centers for Disease Control and Prevention (CDC) guidance. However, less than a third of U.S. adolescents receive even one dose of a neisseria meningitidis group B (MenB) vaccine, and fewer complete the two-dose series, resulting in many adolescents being unprotected against meningococcal disease caused by serogroups A, B, C, W, and Y.^1,2 Routine use of a MenABCWY vaccine could help improve meningococcal vaccination rates and coverage, thereby helping to reduce cases of invasive meningococcal disease and associated mortality.³

"We are very pleased with these positive Phase 3 data, which are the first for a MenABCWY vaccine candidate. A pentavalent vaccine has the potential to help simplify what is currently a complex meningococcal vaccination schedule and improve vaccine coverage. Our goal is to help ensure as many adolescents and young adults as possible are protected against this devastating disease," said Annaliesa Anderson, PhD, Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer.

If approved, this vaccine candidate may help protect more young people from meningococcal disease and supports Pfizer's resolve to become a global leader in the prevention of this disease.